LUX
Life Sciences
Innovation, patient access and pricing are driving the transformation of the life sciences.
This is a time of enormous disruption in the life sciences sector. New IP being generated and new entrants from the technology industry are accelerating the dawn of personalised medicine.
With a nearly constant stream of capital and emerging technologies, biotech startups have proliferated; investors and Big Pharma are chasing innovations, and drug approvals have hit record levels globally.
Talent acquisition has become a key indicator of future success, with well-funded early stage companies and global pharma companies competing on an increasingly level playing field.
Luxembourg
Life sciences in Luxembourg represent an emerging and fast-evolving market. Strong financial and political support has resulted in the development of public research centres, the research-oriented University of Luxembourg, biotech companies, as well as a proliferation of private laboratories and foundations.
Therefore, the life sciences sector is facing important challenges, including attracting and retaining a highly-skilled and multicultural workforce.
At Odgers Berndtson Luxembourg, our team supports biotechnology companies and research centres on developing boards and executive teams.
People
Insights
The age of Precision Medicine
John Jakenfelds looks at the disruptive forces at work in the life sciences arena and the extraor...
Laying down a biomarker
What are the challenges that researchers face in developing personalised medicine – treatment tha...
What next for Medtech?
As the healthcare sector shifts in response to new economic and social trends, recruitment needs...
